Lília Andrade1, Teresa Paiva2,3. 1. Pulmonology Department, Centro Hospitalar Baixo Vouga, Aveiro, Portugal. 2. CENC - Sleep Medicine Center, Campolide, Lisbon, Portugal. 3. Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
Abstract
STUDY OBJECTIVES: This study has as its primary objective to evaluate the quality and effectiveness of type II ambulatory polysomnography (Amb-PSG) versus type I attended laboratory polysomnography (Lab-PSG) in diagnosing obstructive sleep apnea (OSA). Its secondary objective is to evaluate the clinical efficacy, quality of life (QoL), and treatment adherence after diagnosis. METHODS: An observational study of patients with OSA (n = 225) in whom diagnosis was made via Amb-PSG (n = 114) or Lab-PSG (n = 111). Patients' clinical data were retrospectively assessed (including general demographic and clinical data, Epworth Sleepiness Scale, blood pressure, indices from polysomnography, and treatment adherence. Cross-sectional assessment (patient questionnaire) was used to evaluate clinical efficacy indicators, comorbidities, current treatment, and QoL. RESULTS: Polysomnography indices were comparable between Amb-PSG and Lab-PSG (apnea-hypopnea index: 38.9 ± 22.5 versus 35.8 ± 23.1 events/h; P > .05), except for an elevation of total sleep time (510 ± 54.7 versus 476.3 ± 79.4 minutes; P < .01) and loss of oximetry signal (9.8% versus 0.0%; P < .05). Based on polysomnography parameters, OSA was severe in 119 patients (52.9%), moderate in 88 (39.1%), and mild in 18 (8.0%). Diagnostic effect of Amb-PSG in clinical (body mass index, blood pressure, Epworth Sleepiness Scale) and treatment follow-up (CPAP adherence and QoL) indicators was comparable to that of Lab-PSG. CONCLUSIONS: Amb-PSG showed an OSA diagnostic capacity comparable to Lab-PSG. Secondary analyses (diagnostic quality, clinical efficacy, treatment compliance, QoL) underline the value of Amb-PSG as an emerging alternative to improve accessibility to care.
STUDY OBJECTIVES: This study has as its primary objective to evaluate the quality and effectiveness of type II ambulatory polysomnography (Amb-PSG) versus type I attended laboratory polysomnography (Lab-PSG) in diagnosing obstructive sleep apnea (OSA). Its secondary objective is to evaluate the clinical efficacy, quality of life (QoL), and treatment adherence after diagnosis. METHODS: An observational study of patients with OSA (n = 225) in whom diagnosis was made via Amb-PSG (n = 114) or Lab-PSG (n = 111). Patients' clinical data were retrospectively assessed (including general demographic and clinical data, Epworth Sleepiness Scale, blood pressure, indices from polysomnography, and treatment adherence. Cross-sectional assessment (patient questionnaire) was used to evaluate clinical efficacy indicators, comorbidities, current treatment, and QoL. RESULTS: Polysomnography indices were comparable between Amb-PSG and Lab-PSG (apnea-hypopnea index: 38.9 ± 22.5 versus 35.8 ± 23.1 events/h; P > .05), except for an elevation of total sleep time (510 ± 54.7 versus 476.3 ± 79.4 minutes; P < .01) and loss of oximetry signal (9.8% versus 0.0%; P < .05). Based on polysomnography parameters, OSA was severe in 119 patients (52.9%), moderate in 88 (39.1%), and mild in 18 (8.0%). Diagnostic effect of Amb-PSG in clinical (body mass index, blood pressure, Epworth Sleepiness Scale) and treatment follow-up (CPAP adherence and QoL) indicators was comparable to that of Lab-PSG. CONCLUSIONS: Amb-PSG showed an OSA diagnostic capacity comparable to Lab-PSG. Secondary analyses (diagnostic quality, clinical efficacy, treatment compliance, QoL) underline the value of Amb-PSG as an emerging alternative to improve accessibility to care.
Authors: F Portier; A Portmann; P Czernichow; L Vascaut; E Devin; D Benhamou; A Cuvelier; J F Muir Journal: Am J Respir Crit Care Med Date: 2000-09 Impact factor: 21.405
Authors: Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab Journal: J Clin Sleep Med Date: 2007-12-15 Impact factor: 4.062
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Conrad Iber; Susan Redline; Adele M Kaplan Gilpin; Stuart F Quan; Lin Zhang; Daniel J Gottlieb; David Rapoport; Helaine E Resnick; Mark Sanders; Philip Smith Journal: Sleep Date: 2004-05-01 Impact factor: 5.849
Authors: Tarja Saaresranta; Jan Hedner; Maria R Bonsignore; Renata L Riha; Walter T McNicholas; Thomas Penzel; Ulla Anttalainen; John Arthur Kvamme; Martin Pretl; Pawel Sliwinski; Johan Verbraecken; Ludger Grote Journal: PLoS One Date: 2016-10-04 Impact factor: 3.240
Authors: Filip Mivalt; Vaclav Kremen; Vladimir Sladky; Irena Balzekas; Petr Nejedly; Nicholas M Gregg; Brian Nils Lundstrom; Kamila Lepkova; Tereza Pridalova; Benjamin H Brinkmann; Pavel Jurak; Jamie J Van Gompel; Kai Miller; Timothy Denison; Erik K St Louis; Gregory A Worrell Journal: J Neural Eng Date: 2022-02-08 Impact factor: 5.043
Authors: Karin Trimmel; Hans Gerhard Eder; Marion Böck; Andrijana Stefanic-Kejik; Gerhard Klösch; Stefan Seidel Journal: J Clin Sleep Med Date: 2021-05-01 Impact factor: 4.062
Authors: Fiona Kerkamm; Dorothee Dengler; Matthias Eichler; Danuta Materzok-Köppen; Lukas Belz; Felix Alexander Neumann; Birgit Christiane Zyriax; Volker Harth; Marcus Oldenburg Journal: Int J Environ Res Public Health Date: 2021-12-23 Impact factor: 3.390